To include your compound in the COVID-19 Resource Center, submit it here.

Clevudine: Additional Phase III data

Additional data from a 12-week follow-up of an open-label, Korean Phase III trial (study 303) in 54 treatment-naïve patients showed that 31% of HBeAg-positive

Read the full 246 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE